Advanced Oncotherapy #AVO – Update on Distribution Agreement

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that discussions between Yantai Cipu, through its affiliated entity Liquid Harmony, and a major medical equipment and pharmaceutical distribution company in China are continuing beyond the previously announced date of 31 March 2018.  As announced on 16 February 2018, Yantai Cipu informed […]

Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or Intensity-modulated radiation therapy

Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or Intensity-modulated radiation therapy. Author information  Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States; Department of Radiology, Keio University School of Medicine, Tokyo, Japan. Abstract PURPOSE: To […]

Advanced Oncotherapy #AVO – Hardman & Co Research: Confidence greatly boosted

Confidence greatly boosted: Advanced Oncotherapy (AVO) is focused on delivering a more affordable, novel, proton-based radiotherapy system, based on technology developed originally at the world-renowned CERN. Major technical milestones were achieved in 2017 and the company remains on track with its development plan. Confidence has been enhanced significantly with integration of the first three structures and […]

Therapeutic particles – CERN Courier

Therapeutic particles by Virginia Greco, CERN. The accelerator technology underpinning Europe’s first particle-therapy facilities, driven by the TERA Foundation during the past 25 years, is poised to unleash new treatment modes in more compact ways. Last September the TERA Foundation – dedicated to the study and development of accelerators for particle therapy – celebrated its 25th […]

Advanced Oncotherapy #AVO – Holdings in Company

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Advanced Oncotherapy Plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights An acquisition or disposal of qualifying financial instruments which […]

Advanced Oncotherapy #AVO – Completion of the Subscription Agreement

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that in relation to the announcement dated 7 December 2017 and following the passing of the resolution proposed for the vote of the Company’ shareholders on 23 January 2018, the Company has been informed by Yantai Cipu that the Chinese […]

Advanced Oncotherapy #AVO – Result of GM

Advanced Oncotherapy plc (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that at the General Meeting held earlier today, all resolutions were duly passed. For further information contact: Advanced Oncotherapy Plc www.avoplc.com Dr. Michael Sinclair, Executive Chairman Tel: +44 20 3617 8728 Nicolas Serandour, CEO Stockdale Securities (Nomad & Joint Broker) Antonio Bossi […]

Advanced Oncotherapy #AVO – Dr Enrico Vanni director dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that yesterday Dr Enrico Vanni, Non-Executive Director of the Company purchased 40,000 ordinary shares of 25 pence in the Company at a price of 54.5 pence per Ordinary Share. Following this transaction, Dr Vanni now holds 1,263,946 Ordinary Shares, representing 1.56% of the […]